© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Sernova Corp. (SEOVF) stock declined over -1.96%, trading at $0.10 on OTC, down from the previous close of $0.10. The stock opened at $0.11, fluctuating between $0.10 and $0.11 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 0.10 | 0.11 | 0.10 | 0.10 | 346.46K |
| Sep 10, 2026 | 0.10 | 0.11 | 0.10 | 0.10 | 213.8K |
| Sep 09, 2026 | 0.10 | 0.11 | 0.09 | 0.10 | 279.8K |
| Sep 08, 2026 | 0.09 | 0.10 | 0.07 | 0.10 | 567K |
| Sep 04, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 14.2K |
| Sep 03, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 1.02K |
| Sep 02, 2026 | 0.10 | 0.10 | 0.08 | 0.08 | 31.96K |
| Sep 01, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 12K |
| Aug 31, 2026 | 0.08 | 0.09 | 0.07 | 0.09 | 18.7K |
| Aug 27, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 2.24K |
| Aug 26, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 27.47K |
| Aug 25, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 23.9K |
| Aug 21, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 111.41K |
| Aug 20, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 80.7K |
| Aug 18, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 33.05K |
| Aug 17, 2026 | 0.08 | 0.08 | 0.07 | 0.07 | 158.41K |
| Aug 14, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 500 |
| Aug 13, 2026 | 0.08 | 0.08 | 0.07 | 0.07 | 47.85K |
| Aug 11, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 2.02K |
| Aug 10, 2026 | 0.08 | 0.08 | 0.08 | 0.08 | 5.05K |
Sernova Corp. is a Canadian firm, established in 1998 and headquartered in London, that specializes in advanced regenerative medicine therapeutics and is currently in its clinical development phase. The company's primary objective is to innovate and bring to market novel treatments, with a core focus on its unique "Cell Pouch" system. This sophisticated medical device is engineered to create a highly vascularized environment within the body, enabling the successful implantation and integration of therapeutic cells. Once integrated, these cells are designed to continuously release vital proteins or hormones, providing a long-term approach to managing debilitating chronic conditions like diabetes, hemophilia, and thyroid disease. Accompanying the Cell Pouch are related technologies that involve specialized therapeutic cells and methods to shield them from the body's immune response. Sernova actively collaborates with AgeX Therapeutics, Inc. to develop immune-protected therapeutic cells and maintains a research partnership with the University of Miami to further refine its Cell Pouch cell therapy platform.
| Employees | 8 |
| Beta | 0.64 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | October |
| Sector | Healthcare |
| Industry | Biotechnology |